Telemedicine company Hims & Hers Health Inc. shares surged 37.9% in pre-market trading, showing exceptionally strong performance.

This significant surge was triggered by a market report indicating that pharmaceutical giant Novo Nordisk plans to sell its popular weight-loss drugs through the Hims & Hers Health platform. This move is seen as a major endorsement of Hims & Hers' business model and could open up a substantial new revenue stream for the company. Investors responded enthusiastically to the news, driving a sharp increase in the company's market value.